José L. Boyer

TL;DR: There have been many advances in knowledge about different aspects of P2Y receptor signaling since the last review published by the International Union of Pharmacology subcommittee, and more receptor subtypes have been cloned and characterized and most orphan receptors deorphanized, so that it is now possible to provide a basis for a future subdivision of P 2Y receptor sub types.

TL;DR: The cloning of a human G-protein-coupled receptor that specifically responds to UDP-glucose and related sugar-nucleotides has been reported recently and this receptor has important structural similarities to known members of the P2Y receptor family but also shows a distinctly different pharmacological response profile.

TL;DR: Both pharmacological data and the occurrence of selectivity of coupling to second-messenger pathways indicate the existence of multiple members in several of the classes of P2-purinergic receptor subtypes, which couple to G proteins and regulate the inositol lipid, cyclic AMP, and other second-message signaling cascades.

TL;DR: A3P5PS is a competitive P2Y receptor antagonist with a pKB of 6.46 +/- 0.17 and provides a potential new avenue for P2 receptor drug development.

TL;DR: Although the P2Y1‐purinoceptor agonist, 2MeSATP, had no effect on inositol phosphate accumulation in 1321N1 cells infected with the control virus, this agonist markedly stimulated inositl phosphate accumulation with a similar maximal effect to that observed with most agonists tested.